Wyche Keith R
Known title: DirectorCIK: 0001511097
Associated companies
Transaction History
| BCO | ▲ Buy | Option Exercise | 1,844 | $0 | 4/28/2026 | View on chart |
| BCO | ▼ Sell | Open Market | 475 | $50K | 8/11/2025 | View on chart |
| BCO | ▲ Buy | Option Exercise | 1,705 | — | 5/2/2025 | View on chart |
| BCO | ▼ Sell | Open Market | 615 | $60K | 5/16/2024 | View on chart |
| BCO | ▲ Buy | Option Exercise | 2,402 | — | 5/2/2024 | View on chart |
| BCO | ▼ Sell | Open Market | 400 | $33K | 3/5/2024 | View on chart |
| BCO | ▲ Buy | Option Exercise | 1,065 | — | 12/7/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Brink's Gets CMA Approval for NCR Atleos Deal Remedy
Brink's received acceptance in principle from the UK's CMA regarding a proposed remedy for its pending acquisition of NCR Atleos. The company also reported Q2 2026 results and confirmed that a potential sale of UK assets will not impact expected $200M in annual synergies. This regulatory progress is a key step in finalizing the transaction.
Brink's Gets CMA Approval for NCR Atleos Deal Remedy. Brink's received acceptance in principle from the UK's CMA regarding a proposed remedy for its pending acquisition of NCR Atleos. The company also reported Q2 2026 results and confirmed that a potential sale of UK assets will not impact expected $200M in annual synergies. This regulatory progress is a key step in finalizing the transaction.